play the play, don`t let the play play you!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ZIM, red sea crisis stock, Short squeeze ongoing! Short Interest % Float: 24.76 % - AH mover!!!
ZIM, red sea crisis stock, Short squeeze ongoing! Short Interest % Float: 24.76 % - AH mover!!!
Short squeeze ongoing! Short Interest % Float: 24.76 %
ZIM getting more and more attention... -also reddits:
ZIM short squeeze getting traction
No value play, it`s a short squeeze play here!
Different circumstances...!
This one is profiting from side effects from this red sea crisis...
ZIM short squeeze ongoing - Red Sea related!
Short Interest % Float 24.20 %
From wallstreetbets:
ZIM short squeeze getting traction
- ZIM is a container shipping company that operates for 70% on the spot market
- This sector is literally f**ked because of a big amount of new ships that are coming to the market. This crashed the shipping rates and is the reason why shorters attacked this share. 25% short interest is the result and in my opinion, they were right
- However, the Red Sea attacks made sure that now 20% of the container transport worldwide needs to travel below Africa instead of the Red Sea (which will probably increase even a bit now). This takes 2 extra weeks and is the reason why shipping rates are exploding
- Interesting for ZIM, because the share crashed a lot. From 84,50 to 7 dollars. The market is pricing in years of losses now for ZIM, but because of the Red Sea attacks, this scenario is in my opinion temporarily gone
Long story short: ZIM is not a buy-and-hold. In shipping, you have a few good quarters or years and then just pain follows most of the time. ZIM can perhaps have a great quarter or 2/3 because of the attacks now. Now the market is pricing this in, you can see a big reaction.
ZIM integrated shipping stock prime beneficiary red sea disruptions: buy
(Article from 03 Jan 03, 2024)
https://seekingalpha.com/article/4661278-zim-integrated-shipping-stock-prime-beneficiary-red-sea-disruptions-buy
ZIM short squeeze ongoing - Red Sea related!
Short Interest % Float 24.20 %
From wallstreetbets:
ZIM short squeeze getting traction
- ZIM is a container shipping company that operates for 70% on the spot market
- This sector is literally f**ked because of a big amount of new ships that are coming to the market. This crashed the shipping rates and is the reason why shorters attacked this share. 25% short interest is the result and in my opinion, they were right
- However, the Red Sea attacks made sure that now 20% of the container transport worldwide needs to travel below Africa instead of the Red Sea (which will probably increase even a bit now). This takes 2 extra weeks and is the reason why shipping rates are exploding
- Interesting for ZIM, because the share crashed a lot. From 84,50 to 7 dollars. The market is pricing in years of losses now for ZIM, but because of the Red Sea attacks, this scenario is in my opinion temporarily gone
Long story short: ZIM is not a buy-and-hold. In shipping, you have a few good quarters or years and then just pain follows most of the time. ZIM can perhaps have a great quarter or 2/3 because of the attacks now. Now the market is pricing this in, you can see a big reaction.
ZIM short squeeze ongoing - Red Sea related!
Short Interest % Float 24.20 %
From wallstreetbets:
ZIM short squeeze getting traction
- ZIM is a container shipping company that operates for 70% on the spot market
- This sector is literally f**ked because of a big amount of new ships that are coming to the market. This crashed the shipping rates and is the reason why shorters attacked this share. 25% short interest is the result and in my opinion, they were right
- However, the Red Sea attacks made sure that now 20% of the container transport worldwide needs to travel below Africa instead of the Red Sea (which will probably increase even a bit now). This takes 2 extra weeks and is the reason why shipping rates are exploding
- Interesting for ZIM, because the share crashed a lot. From 84,50 to 7 dollars. The market is pricing in years of losses now for ZIM, but because of the Red Sea attacks, this scenario is in my opinion temporarily gone
Long story short: ZIM is not a buy-and-hold. In shipping, you have a few good quarters or years and then just pain follows most of the time. ZIM can perhaps have a great quarter or 2/3 because of the attacks now. Now the market is pricing this in, you can see a big reaction.
ZIM - Red Sea related stock!
Article from german stock portal, Jan 04, 2024 Threat in the Red Sea - Freight rates are exploding - so are shipping stocks!:
Google-Translation:
Threat in the Red Sea - Freight rates are exploding - so are shipping stocks!
The repeated attacks by Yemen's Houthi rebels on ships in the Red Sea are causing freight rates to explode - shipping stocks such as Hapag Lloyd and ZIM Integrated are rising.
Summarized for you
Freight rates skyrocket due to attacks in the Red Sea
Detours around the Horn of Africa increase transport costs
Shipping companies benefit, shipping stocks rise
The ongoing attacks on cargo ships in the Red Sea have long had tangible consequences for the markets. The prices for oil and gas rise with every new attack, but now freight rates have also exploded.
The shipping companies are preparing for the danger posed by the Iranian-financed rebels and are increasingly forgoing passage through the Suez Canal.
For some shipping routes, this means a week-long detour around the Horn of Africa, reducing overall available freight capacity and causing transport costs to skyrocket.
Costs are sometimes doubled
The cost of shipping a standard container from Asia to Europe has doubled in the past few weeks to over $4,000. Transports to the Mediterranean region have become even more expensive, costing over $5,000.
However, due to dwindling transport capacities, routes that are not geographically affected have also become significantly more expensive. The cost of a container from Southeast Asia to the USA has skyrocketed by around 60 percent. This could make it much more difficult to combat inflation in the coming months.
Shipping companies benefit, shipping stocks in demand
Even though the detours sometimes mean delays lasting weeks, shipping companies are profiting from the rapidly rising transport costs. Freight companies that specialize in short-term contracts in particular are benefiting from the sharp rise in spot prices.
In recent days, the shares of Danaos and ZIM Integrated, two of the largest specialists in this niche, have become particularly expensive.
In addition to smaller providers specializing in the spot market, well-known names such as the German Hapag Lloyd, which is now trading at double-digit price premiums, and the Danish A.P. Moeller-Maersk, the world's largest container ship shipping company, was asked.
The price gains of the past few days are likely to please quite a few investors, as many shipping stocks have been in stable downward trends since the beginning of 2022 at the latest, when global freight rates reached their peak.
With rates now becoming more expensive again, a bottom could be found and the industry could be ripe for a turnaround.
Something for everyone
Conservative investors should particularly look at Danaos, Hapag Lloyd and A.P. Take a closer look at Moeller-Maersk; these shipping companies reliably pay out a performance-related dividend.
ZIM Integrated is worth a look for traders and risk-conscious investors: the stock has a short ratio of over 24 percent. If the price gains of the previous days continue, there could be a short squeeze and a price explosion.
Conclusion: Good hedge, promising despite dangers
Shipping stocks are in demand not despite, but because of the current threat situation and are a good hedge against the potential effects of a lasting impairment of global shipping. Meanwhile, the breadth of the industry offers opportunities for all types of investors.
Amazon to win unconditional EU nod for iRobot deal: sources
(The original article)
Thu, November 23, 2023 at 2:45 AM MST·1 min read
https://finance.yahoo.com/news/exclusive-eu-approve-amazons-irobot-094503258.html
BRUSSELS (Reuters) — Amazon (AMZN) is set to win unconditional EU antitrust approval for its $1.4 billion acquisition of robot vacuum maker iRobot, three people familiar with the matter said on Thursday.
Antitrust enforcers around the world have stepped up scrutiny of Big Tech acquiring smaller rivals, concerned about the accumulation of troves of data by a few companies and big players leveraging their dominance into new markets.
The European Commission, which acts as the EU's competition watchdog, warned Amazon in July that the deal could reduce competition in robot vacuum cleaners and reinforce the U.S. company's dominant position as an online marketplace provider.
The Commission, which is due to decide on the deal by Feb. 14, declined to comment. Amazon did not respond immediately to a request for comment.
The UK antitrust agency cleared the deal unconditionally after a preliminary review.
(Reporting by Foo Yun CheeEditing by Mark Potter and David Goodman)
Amazon to win unconditional EU nod for iRobot deal: sources
(The original article)
Thu, November 23, 2023 at 2:45 AM MST·1 min read
https://finance.yahoo.com/news/exclusive-eu-approve-amazons-irobot-094503258.html
BRUSSELS (Reuters) — Amazon (AMZN) is set to win unconditional EU antitrust approval for its $1.4 billion acquisition of robot vacuum maker iRobot, three people familiar with the matter said on Thursday.
Antitrust enforcers around the world have stepped up scrutiny of Big Tech acquiring smaller rivals, concerned about the accumulation of troves of data by a few companies and big players leveraging their dominance into new markets.
The European Commission, which acts as the EU's competition watchdog, warned Amazon in July that the deal could reduce competition in robot vacuum cleaners and reinforce the U.S. company's dominant position as an online marketplace provider.
The Commission, which is due to decide on the deal by Feb. 14, declined to comment. Amazon did not respond immediately to a request for comment.
The UK antitrust agency cleared the deal unconditionally after a preliminary review.
(Reporting by Foo Yun CheeEditing by Mark Potter and David Goodman)
AMZN paying $51.75/share for IRobot, IRBT currently around $39! $$$-bargain!!!
AMZN paying $51.75/share for IRobot, IRBT currently around $39! $$$-bargain!!!
Right! $51.75/share
iRobot breaking news:
Exclusive: Amazon to win unconditional EU nod for iRobot deal
Amazon offer is $51 !!!
iRobot breaking news:
Exclusive: Amazon to win unconditional EU nod for iRobot deal
Amazon offer is $51 !!!
Exclusive: Amazon to win unconditional EU nod for iRobot deal -sources
iRobot takeover going through
$$$ Great new article on ACIU $$$
https://www.labiotech.eu/in-depth/vaccine-parkinsons-disease/
$$$ Great new article on ACIU $$$
https://www.labiotech.eu/in-depth/vaccine-parkinsons-disease/
$$$ Great new article on ACIU $$$
https://www.labiotech.eu/in-depth/vaccine-parkinsons-disease/
ACIU CEO: expecting "to have the first immunogenicity data by the end of the year."
"According to Pfeifer, it is only a matter of time before the company announces the dosing of the first patients and, if everything goes to plan, they expect to have the first immunogenicity data by the end of the year."
https://www.labiotech.eu/in-depth/vaccine-parkinsons-disease/
ACIU CEO: expecting "to have the first immunogenicity data by the end of the year."
"According to Pfeifer, it is only a matter of time before the company announces the dosing of the first patients and, if everything goes to plan, they expect to have the first immunogenicity data by the end of the year."
https://www.labiotech.eu/in-depth/vaccine-parkinsons-disease/
ACIU currently developing vaccine for Parkinson’s!!!
"The current approach to Parkinson’s vaccines is the introduction of a molecule that induces the body to produce its own antibodies against alpha-synuclein, leading to active immunity. In doing this, the idea is that the antibodies will bind to clumped alpha-synuclein and help to break them down.
One of the specific benefits of creating a vaccine for Parkinson’s comes in the form of both efficiency and cost-effectiveness. As Mei Mei Hu, CEO of Vaxxinity, pointed out, “as a modality for delivering medicine, vaccines are easy to take, easy to make, and inexpensive to produce.
Pfeifer also agreed with this sentiment and said that AC Immune hopes to be able to get away with only giving one or two vaccinations per year with its vaccine candidate, which is important not just from a cost perspective, but also a convenience standpoint."
From article "Is a vaccine for Parkinson’s disease possible?"
ACIU currently developing vaccine for Parkinson’s!!!
"The current approach to Parkinson’s vaccines is the introduction of a molecule that induces the body to produce its own antibodies against alpha-synuclein, leading to active immunity. In doing this, the idea is that the antibodies will bind to clumped alpha-synuclein and help to break them down.
One of the specific benefits of creating a vaccine for Parkinson’s comes in the form of both efficiency and cost-effectiveness. As Mei Mei Hu, CEO of Vaxxinity, pointed out, “as a modality for delivering medicine, vaccines are easy to take, easy to make, and inexpensive to produce.
Pfeifer also agreed with this sentiment and said that AC Immune hopes to be able to get away with only giving one or two vaccinations per year with its vaccine candidate, which is important not just from a cost perspective, but also a convenience standpoint."
From article "Is a vaccine for Parkinson’s disease possible?"
ACIU, 11 product candidates ag. Alzh. & PD in pipeline !
ACIU pipeline
ACIU, 11 product candidates ag. Alzh. & PD in pipeline !
ACIU pipeline
$$$ ACIU, tracer for Alzheimer in phase 3! $$$
$$$ ACIU, tracer for Alzheimer in phase 3! $$$
ACIU biotech gem @$2.17, partnering with Eli Lilly!
AC Immune & Eli Lilly
ACIU biotech gem @$2.17, partnering with Eli Lilly!
AC Immune & Eli Lilly
ACIU @$2.15, huge collaboration with Eli Lilly & Genentech!
ROBUST PIPELINE Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases
"Based on our SupraAntigen® and Morphomer® technology platforms, we are advancing one of the industry’s broadest and most diverse clinical-stage pipelines focused on neurodegenerative diseases.
We design first- and best-in-class therapeutic and diagnostic candidates to tackle established and novel disease targets enabling AC Immune’s comprehensive precision medicine approach."
ACIU @$2.15, huge collaboration with Eli Lilly & Genentech!
ROBUST PIPELINE Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases
"Based on our SupraAntigen® and Morphomer® technology platforms, we are advancing one of the industry’s broadest and most diverse clinical-stage pipelines focused on neurodegenerative diseases.
We design first- and best-in-class therapeutic and diagnostic candidates to tackle established and novel disease targets enabling AC Immune’s comprehensive precision medicine approach."
ACIU @$2.15, huge collaboration with Eli Lilly & Genentech!
ROBUST PIPELINE Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases
"Based on our SupraAntigen® and Morphomer® technology platforms, we are advancing one of the industry’s broadest and most diverse clinical-stage pipelines focused on neurodegenerative diseases.
We design first- and best-in-class therapeutic and diagnostic candidates to tackle established and novel disease targets enabling AC Immune’s comprehensive precision medicine approach."
w/ACIU @$2.20, biotech neuroimaging, Email:
"Our PET tracer, ACI-12589, is the only tracer to have generated live images of a-syn in human brains, giving us the most advanced program. ACI-12589 effectively distinguished Multiple System Atrophy (MSA) from healthy controls and other a-synucleinopathies, including Parkinson’s disease, Lewy Body Dementia and other NDDs. We are now working to build on these exciting results to declare a new clinical candidate specifically for development in Parkinson Desease
In this context, AC Immune’s research is pioneering. When it comes to neuroimaging, i.e. measuring and localizing a-syn quantitatively in the brain, our tracer program is first- and best-in-class."
w/ACIU @$2.20, biotech neuroimaging, Email:
"Our PET tracer, ACI-12589, is the only tracer to have generated live images of a-syn in human brains, giving us the most advanced program. ACI-12589 effectively distinguished Multiple System Atrophy (MSA) from healthy controls and other a-synucleinopathies, including Parkinson’s disease, Lewy Body Dementia and other NDDs. We are now working to build on these exciting results to declare a new clinical candidate specifically for development in Parkinson Desease
In this context, AC Immune’s research is pioneering. When it comes to neuroimaging, i.e. measuring and localizing a-syn quantitatively in the brain, our tracer program is first- and best-in-class."
w/ACIU @$2.20, biotech neuroimaging, Email:
"Our PET tracer, ACI-12589, is the only tracer to have generated live images of a-syn in human brains, giving us the most advanced program. ACI-12589 effectively distinguished Multiple System Atrophy (MSA) from healthy controls and other a-synucleinopathies, including Parkinson’s disease, Lewy Body Dementia and other NDDs. We are now working to build on these exciting results to declare a new clinical candidate specifically for development in Parkinson Desease
In this context, AC Immune’s research is pioneering. When it comes to neuroimaging, i.e. measuring and localizing a-syn quantitatively in the brain, our tracer program is first- and best-in-class."
w/ACIU, AC Immune Case Study:
Pioneering precision medicine to diagnose, treat, and prevent neurodegeneration
"AC Immune’s research is pioneering. When it comes to neuroimaging, i.e. measuring and localizing a-syn quantitatively in the brain, our tracer program is first- and best-in-class"
w/ACIU, AC Immune Case Study:
Pioneering precision medicine to diagnose, treat, and prevent neurodegeneration
"AC Immune’s research is pioneering. When it comes to neuroimaging, i.e. measuring and localizing a-syn quantitatively in the brain, our tracer program is first- and best-in-class"
w/ACIU, gem @$2.20: "AC Immune’s research is pioneering. When it comes to neuroimaging, i.e. measuring and localizing a-syn quantitatively in the brain, our tracer program is first- and best-in-class"